David O’Connell, director of Scientific Affairs at PCI Pharma Services, Tredegar site, shares insight on how CDMOs, like PCI, can provide end-to-end solutions in the growing demand of high potency manufacturing.
Drug products containing high potency active pharmaceutical ingredients (HPAPIs) continue to be a major driving force in the global pharmaceutical market. Consequently, Contracted Development and Manufacturing Organisations (CDMOs) that are able to provide end-to-end solutions for the development and manufacture of highly potent solid oral dosage forms remain a vital part of the pharmaceutical outsourcing industry.